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Abstract
Cohort studies employ pairwise measures of association to quantify
dependencies among conditions and exposures. To reliably use these mea-
sures to draw conclusions about the underlying association strengths re-
quires that the measures be robust and unbiased. These considerations
assume greater significance when applied to disease networks, where asso-
ciations among heterogeneous pairs of diseases are ranked. Using disease
diagnoses data from a large cohort of 5.5 million individuals, we develop
a comprehensive methodology to characterize the bias of standard asso-
ciation measures like relative risk and φ correlation. To overcome these
biases, we devise a novel measure based on a stochastic model for disease
development. The new measure is demonstrated to have the least overall
bias and hence would be most suitable for application to heterogeneous
disease cohorts.
1 Introduction
Population cohort is used in epidemiological and medical research to infer im-
portant relationships between diseases and related factors. These relationships
are deduced based on statistical measures [1, 2] employed to quantify the nature
and degree of association.
The validity of inferences made using such measures therefore depends on the
consistency and robustness of the measure. In qualitative terms, a pairwise
association measure should represent the ‘true interaction’ between a pair of
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diseases and this should be correctly identified for a wide range of disease pairs.
We say that a measure has a bias when there is a systematic dependence of
its evaluation on some characteristic of the disease pair, such as the prevalence
rate of eiher disease. These issues acquire an even greater significance when
considering comparison and rankings of disease pais of a heterogeneous dataset
as in the case of disease networks [3, 4, 5].
The straightforward approach to investigate this potential problem would be to
simulate several pairs of diseases with a similar ‘interaction’ but differing with
respect to the other quantities (those independent of joint co-occurrence) and
determining if there is a systematic dependence of the measure on these quan-
tities. The difficulty with this approach is that there is no objective definition
of ‘interaction’ of a pair of diseases; indeed, the measure is trying to precisely
capture this, leading to circularity in the problem statement. And yet, this
phenomena does not arise from an artifice in semantics; its origins lie in our
lack of understanding of how a pair of related diseases interact.
In cross-sectional studies, where statistical associations are only cautiously inter-
preted as potential causal relations [6], this lack of understanding is accepted.
Nonetheless, what is less appreciated is how similar values of association ob-
tained by applying a single measure may reflect different extents of true asso-
ciation, even when other sources of bias such as selection type or confounder
effect is absent.
Although there have been studies describing the differences in measure proper-
ties and suggested procedures for domain-specific selection [7, 8], to the best of
our knowledge, there has been no systematic approach to examine the bias in
association measures in the context of diseases. The basis of such an approach
would be a large cohort data where measure bias would be empirically deter-
mined. Importantly, the difficulty of accurate simulation of disease associations
discussed earlier is directly overcome with a dataset consisting of prevalence and
co-occurrence of a heterogeneous set of diseases. This enables us to define bias
by systematic over or under estimation of associations depending on underlying
putative bias variables. This also provides an unambiguous method to compare
the bias of different measures.
In this work, we use recorded diagnoses for a cohort R of all 5.5 million people
living in Sweden followed prospectively for 13 years. We develop a systematic
methodology to characterize the biases of standard measures of associations be-
tween disease pairs in this cohort. With the aim of understanding the impact of
bias on effect-size calculations, we quantify the bias using three distinct indices.
Our analysis conclusively demonstrates the prevalence and nature of measure
bias in cross-sectional studies and provides insights into its origins.
To address these biases, we derive, from first principles, a novel measure family
using stochastic model of disease development with differential rate of diagnosis.
The new measure shows significantly better performance uniformly across a wide
range of parameter considerations and bias variables. Overall we find the least
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bias with the new measure among all those that were considered. We repeat
the same analysis with the U.S. Medicare data of 32 million individuals and
once again, find that our new measure outperforms all others. We thus provide
theoretical justification for its proposal using the stochastic model and empirical
demonstration of its characteristics using two large datasets.
2 Measure Bias
2.1 Association measures
We introduce the framework for characterizing bias by considering two com-
monly used measures for pairwise associations, relative risk (RR) [9, 10] and
φ−correlation [11, 12]. RR and the family of measures similar to it such as odds
ratio [13, 14], hazard ratio, and Yule’s Q [15] are based on relative probabilities
of occurrence of diseases in different conditions. To consider these measures in
more general terms, we define the 2×2 contingency table (Table 1) for a disease
pair A and B, where the top-left entry p represents the number of individuals
having both diseases, q, the number having B but not A and similarly for the
entries on the second row. N = p+ q+ r+ s is the total number of individuals.
The relative risk for disease A, in the presence of B is the ratio of prevalence of
A in the subset diagnosed with B to the prevalence in the subset not diagnosed
with B. :
RRA|B =
p/(p+ q)
r/(r + s)
(1)
and likewise, swapping A and B
RRB|A =
p/(p+ r)
q/(q + s)
It should be noted that the original definition of relative risk considers disease
incidence among sets exposed and not exposed to a given condition. This ex-
plains the asymmetry in the above definition, where presence of a disease is
considered as an exposure condition. However, we cannot apply the original
interpretation directly to the cohort when the order of occurrence of the disease
pair in an individual is unknown. Despite that, we can make simplifying as-
sumptions for large cohort, and this is precisely the definition used in previous
studies involving disease networks [3, 12]. As the individual disease prevalences
in our cohort is small, we can assume that
p/s, q/s, r/s << 1.
Further if we assume that
p/r, p/q << 1,
3
which effectively implies that prevalence of one disease within the subset of
patients having another disease to also be very small, it is easy to show that the
reduced expressions for both are identical.
RRA|B ∼ pN
nAnB
(2)
We find that the expression in the last line above is explicitly symmetric in the
two diseases.
A related measure, odds ratio [16] for the same contingency table is given by:
OR =
p/q
r/s
=
ps
qr
(3)
Unlike RR, odds ratio is explicitly symmetric in the two diseases, and further
it is easy to show that, in the limit that we are interested in, where prevalence
rates are assumed to be small, they converge to the same value.
ps
qr
=
pN
nAnB
1
1 + (p+ q + r)/s
(1 + p/r)(1 + p/q) ∼ pN
nAnB
φ correlation:
Another common measure used for contingency table is the φ correlation and
measures that reduce to a similar form include Cohen’s κ [17] and Kendall’s τb
[18].
The φ correlation is obtained by taking the standard correlation between the
binary vectors corresponding to the two diseases. For a given disease A, the
corresponding vector is of length equal to the number of patients and each
entry is 1(0) depending on the disease being present (absent) in that individual.
φA,B =
p
N − nAnBN2√
nA
N
nB
N
(
1− nAN
) (
1− nBN
) (4)
Equivalently, it can be defined as
√
χ2/N where χ2 is chi-squared statistic
calculated for the contingency table.
2.2 Formulating measure bias
Let D be the dataset from a cohort of N individuals and K potential disease
diagnoses. For each individual p, we represent their diagnoses using a vector
of binary indicator variables (Ap1, A
p
2, · · ·ApK) where Api is 1(0) depending on
the presence (absence) of disease i. For any arbitrary pair of distinct diseases
(i, j), let nuv =
∑
p
1[Api = u]1[A
p
j = v] (u, v ∈ {0, 1}) where 1[.] is 1(0) if the
condition expressed in [.] evaluates to true(false). Define the marginal nu+ =
4
nu0 + nu1 for u = 0, 1 and likewise for n+v. By definition,
∑
u=0,1;v=0,1
nuv = N .
For a given measure µ let P (µ) be its distribution across all pairs of diseases
in the cohort. We say that the measure has a bias with respect to variable W
(W is some characteristic of the disease pair prevalence) if there is a systematic
dependence of the measure conditioned on that variable, i.e., P (µ|W ) is some
non-trivial function of W .
It is important to note that this definition of bias is empirical. The existence or
non-existence of bias in a given measure is dependent on the nature of associa-
tions found in the dataset. A measure may show considerable bias when applied
to a disease cohort but may be well-suited (i.e., show no bias) when measuring
association between developmental indices of nations. This is qualitatively dif-
ferent from identifying general properties that a measure is required to satisfy
[19, 20] although it is generally accepted that identifying the property that is
most relevant depends on the specific context [7].
Define F to be the set of distinct diseases (classified by ICD 10 three-character
precision) in our cohort R with K = |F| > 1400 . We investigate measure bias
by considering variables W that are likely to affect the measure characteristics.
We first examine potential bias with respect to the expected co-occurrence under
the assumption of independence of the diseases, i.e., if nA, nB represent the
prevalence of a given disease pair (A,B) then W = n
(0)
AB = N
nA
N
nB
N =
nAnB
N .
Observe that there is no a priori reason to expect the distribution of the measure
to depend on it.
In line with our formulation, we partition the set of all disease pairs D into M
(20 in this case, but it could be any reasonable number so that one can get
reliable statistics within each interval and at the same time, be able to discern
the overall trend across intervals) mutually exclusive subsets Dj , j = 1, 2, · · ·M .
D = {{A,B}|A,B ∈ F} = ∪Mj=1Dj
where Dj = {{A,B}|vj−1 < n(0)AB < vj} The intervals vj are determined by
the requirement that each of these partitions contain the same number of pairs
|D0| = · · · |Dj | = · · · |DM |. Next we apply the measures within each partition
to identify systematic dependence, if any. We begin with RR (Eq. 2) and
Fig. 1a shows the box plot of the distribution of the measure values within
each partition. We find unambiguous systematic bias where low expected co-
occurrence leads to higher values of RR. Equally significant is the variation
of size of the box representing the boundaries of the 25th and 75th percentile
(interquartile range) for the collection of RR values in each partition. This
increase is even more pronounced than that of the median, as the expected
co-occurrence decreases.
We can explain the large spread by noting that, for lower expected co-occurrences,
small fluctuations in co-occurrence numbers leads to wide variations in RR. Un-
der the assumption of the independence of a disease pair, we can show that
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the distribution of co-occurrences (for a given disease pair) is Poisson with
mean being the expected co-occurrence (see Appendix B). As the variance of
a Poisson distribution is equal to the mean, the coefficient of variation is given
by
√
n
(0)
AB/n
(0)
AB =
1√
n
(0)
AB
, representing an inverse relation with expected co-
occurrence .
The same analysis is repeated for the φ correlation and Fig. 1b shows the box
plot for this case. A systematic bias is once again immediate from inspecting
the figure, except that the bias points in the opposite direction: φ correlation
tends to inflate the associations for higher expected co-occurrences.
We thus find that both RR and φ correlation have significant bias with re-
spect to the expected co-occurrence, except that the bias works in opposite
directions. Where RR tends to assign higher associations to disease pairs with
lower expected co-occurrence, the exact opposite it true for the φ correlation.
Conversely, higher expected co-occurrences lead to lower RR and higher φ cor-
relation. Note that lower (higher) expected co-occurrences arise when one or
both diseases have low (high) prevalence.
2.3 Quantifying measure bias
Since both RR and φ correlation show bias, we want to compare their magnitude
of bias. This requires a scheme to correctly identify and quantify the bias for any
given measure. It has long been recognized in clinical and observational studies
and in epidemiology that null hypothesis tests for associations are of only limited
use [21, 22]. Specifically, the rejection of the null-hypothesis and the significance
level at which it is rejected does not signify the degree of association. Hence
effect-sizes are necessary where the strength of association is important [23] as
is likely true in most realistic cases.
Selection based on minimum effect-size is equivalent to setting a threshold (as-
suming everything else to be fixed) for the measure. We want to characterize
bias in terms of its impact on selection. For definiteness, assume that we are
interested in the subset of pairs comprising the top f fraction of D (as deter-
mined by a given measure). We can equivalently express this in terms of a
threshold (θ(f)) where all pairs with measure values greater than the threshold
are selected. If the same threshold is then independently applied to the pairs in
every partition for the bias variable, a fraction fj of pairs within each subset is
selected. If there is no bias, then these fractions would be identical; conversely
the extent of variation of the fractions across the partitions will be treated as a
proxy for the bias.
Fig. 2a shows the selected fractions for RR and φ correlation measures when the
overall fraction f sought is 0.01 (i.e, we set a threshold such that only 1% of all
pairs are greater than that threshold) with expected co-occurrences as the bias
variable. As expected the stringency of the selection depends on the partition,
with larger fractions being chosen for lower expected co-occurrences in the case
of RR (and the opposite for φ correlation).
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This approach of using fractions to understand bias has a distinct advantage
of treating all measures on an equal footing. The fractions represent the effect
of the measure on the result of querying the data-set. To capture the extent
of variation of fractions across the different partitions, with emphasis on its
impact, we define a set of indices to characterize them. The naive approach of
using standard deviation is unsatisfactory because these fractions are typically
not normally distributed. We propose three different indices that helps us better
understand the bias.
1) Interquartile range (IQR): IQR measures difference in the location of the
75th and 25th quartile of the distribution of fractions. IQR characterizes the
range within which the half of the data around the median is located.
2)Mean Absolute Deviation (MAD): This weighs all deviations from the
mean equally. MAD is preferred over the mean squared deviation because the
underlying distribution need not be normal.
2)Q9Q1 : To capture the most severe effect of the variation of the fractions
across the bias variable, we define Q9Q1 as
q0.9({f})
q0.1({f}) , where qx(B) represents
the 100xth quantile of B. This ratio of fractions (identified as significant) that
are in 90th and 10th quartile emphasizes the extreme effect of the bias on
comparisons.
The result of applying the three indices to the fractions shown in Fig. 2a is
shown in Fig. 2b. We find that the Q9Q1 score has a largest gap for the two
measures, and RR’s bias is indeed very high (note the y-axis is logarithmic),
suggesting that the effect of the bias on RR is more severe compared to φ
correlation, when comparing two disease pairs whose expected co-occurrences
differ widely. There is not much separating the two measures in terms of IQR
or MAD.
To appreciate that our approach to studying bias is methodologically sound,
we must view the partitioning and the resulting fractions as an approximation
to the function hTh(θ) representing the fraction of pairs selected for the bias
variable θ with Th being a specific threshold. If q(θ) represent the density of
pairs in the population corresponding to θ, then in the continuum limit, the
three indices would be defined as:
(i) IQRc = hTh(θ0.75) − hTh(θ0.25) where θx is given by the solution to the
integral: ∫ θx
0
q(θ)dθ = x
(ii) MADc =
∫
q(θ)|hTh(θ)− h¯Th|dθ where h¯Th is the mean.
(iii) Q9Q1c =
hTh(θ0.9)
hTh(θ0.1)
The definitions of these indices based on finite fractions can then be seen as
straightforward discretized approximations to their continuum definitions.
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2.3.1 Prevalence ratio bias
The ratio of the prevalences of the two diseases as a possible bias for mea-
sures has been considered before [24, 19]. We follow a similar approach as with
expected-co-occurrence and partition all pairs based on W = n<n> , where n<(n>)
represents the prevalence of the less (more) prevalent disease in the pair. We use
the same threshold on RR and φ such that 1% of all pairs are selected overall.
The variation of the fractions is shown in Fig. 3a and we find that φ correlation
shows larger differences in fractions, with distinctly suppressed numbers for low
prevalence ratios. RR is relatively more balanced and this fact is also reflected
in the three indices shown in Fig. 3b.
2.3.2 Modified φ correlation
The bias of φ correlation with respect to the prevalence ratio can be explained
by noting that φ has an upper bound that depends on the ratio of prevalences.
Assuming disease pairs with prevalence nA < nB
φ(1, 2) =
nAB/N − (nA/N)(nB/N)√
(nA/N)(nB/N)(1− nA/N)(1− nB/N)
<=
min{nA, nB}/N − (nA/N)(nB/N)√
(nA/N)(nB/N)(1− nA/N)(1− nB/N)
=
(nA/N)(1− nB/N)√
(nA/N)(nB/N)(1− nA/N)(1− nB/N)
=
√
nA
nB
1− nB/N
1− nA/N
<
√
nA
nB
Thus the maximum possible association between two diseases is not a constant
but depends on their prevalence ratio [19]. This suggests that disease pairs
with a high disparity in prevalences would systematically have lower values of
φ correlation and indeed this is what we observed in Fig. 3a.
A quick workaround of this problem is defining a modified φM = nAB/N−(nA/N)(nB/N)min{nA/N,nB/N} ,
which has a uniform upper bound of unity, attained when co-occurrence nAB =
min{nA, nB}. Fig. 4a compares the original correlation and the new modified
version. We immediately observe the correction offered by φM to the original
correlation goes past the required bias removal: the measure shows a bias in the
opposite direction, tending to select greater fraction for more dissimilar preva-
lence ratios [25]. The three indices in Fig. 4b shows that φM in fact has higher
bias than φ.
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3 Novel measure
We propose a conceptual and systematic approach to define a new measure of
association and leading to a family parametrized by a constant γ
φγ =
(n1n2
N
) n12
N − n1n2N2(
n1+n2
N
)2 − (n1−n2N )2 γ . (5)
The full derivation of this measure (Eq. 19) is given in the Methods section but
the approach and motivation is as follows. We formulate the association between
a pair of diseases in terms of the differential rate of development of one disease in
the presence or absence of the other. We then use stochastic differential equation
to evolve the disease probabilities in time and use the contingency table entries
as constrains to estimate these rates. Since these rates are a priori unknown, and
there are more variables than equations, we further use an additional constraint
to choose a unique solution (the parameter γ originates from the constraint
equation).
Defining φM2 as the measure corresponding to γ = 1:
φM2 = φγ=1.0 =
(
n1 + n2
N
) n12
N − n1n2N2
4n1n2N2
(6)
The justification of the choice for γ is given in the Supplement, along with a
discussion of the measure properties. The fractions obtained when pairs are
partitioned by prevalence ratio for φ, φM and φM2 are compared in Fig. 5a.
Visual inspection suggests that φM2 is the most balanced among them. The
corresponding indices in Fig. 5b confirm our observations that φM2 has the least
bias for all three indices, and while standard correlation performs comparably
well with MAD, φM2 is significantly better than both the other measures with
IQR and Q9Q1.
3.1 Comparison across threshold fractions
We have thus far demonstrated that the new measure has the least bias with
respect to prevalence ratio compared to other correlation measures. However,
this was done for a specific setting of threshold, such that an overall 1% of pairs
are selected. The next step is to determine if that reduction in bias is valid
for a wider range of fractions. Indeed, the threshold setting for determining
significant pairs would depend on the context of the inquiry.
A comprehensive comparison of the four measures (RR, φ, φM and φM2) is
done across five different thresholds (corresponding to overall fraction of selected
pairs, 0.1,0.05,0.01,0.005 and 0.001). The basis of comparison is the three indices
(IQR, MAD, Q9Q1), taken one at a time.
Fig. 6a,b and c shows the relative performance of all measures according to
IQR, MAD and Q9Q1 respectively when bias variable is the prevalence ratio.
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We find, for example, from the first two sublots for IQR and MAD, that φM2
has the least bias for threshold fractions less than or equal to 0.01 but has
significantly more bias than RR for higher fraction of selections. For Q9Q1,
φM2 has the least bias for overall fractions less than or equal to 0.001. At the
other end, either φ or φM have the highest bias for any given overall fraction
and any given index.
It is clear that, although the new measure φM2 is consistently better than the
two correlation measures, RR has lower bias when the selected fractions are
higher. There is nothing unexpected about this because the new measure was
devised to eliminate the bias in φ and φM only. While it may be tempting to go
with RR for higher threshold fractions, we cannot prematurely conclude that
until we consider the bias due to the expected co-occurrence as well.
Figures 7a,b and c explore the biases with respect to the expected co-occurrence
using IQR, MAD and Q9Q1 indices respectively. We find that, although we had
observed in Fig. 6 that RR performed well for overall fractions greater than or
equal to 0.05, this is not the case when we examine the bias due to expected
co-occurrence. Both MAD and Q9Q1 indices show RR having the highest bias
for these thresholds.
Although the different indices characterize different aspects of the bias (rankings
of measures by a pair of indices need not be concordant as we can see in the
above figures), it is still useful to define a combined score based on all the three
indices and both the bias variables. We define such a score s as the net bias
s = (IQR)E(MAD)E(Q9Q1)E + (IQR)P (MAD)P (Q9Q1)P (7)
where the subscripts E,P for each index represent the bias variable expected
co-occurrence and prevalence ratio respectively.
Fig. 8 shows that, across all the thresholds considered over three orders of
magnitude, φM2 has the best overall performance with the least s among all
measures. Greater the stringency of selection, greater is the performance gain
that is observed.
To ensure that the bias reduction obtained with the new measure is not limited
only to our cohort, we also applied these measures to another large publicly
available dataset. The cohort data consists of inpatient claims of 32 million
individuals enrolled in the U.S. Medicare program between 1990 and 1993, and
this dataset is used in one of the early publications on disease networks [3], and
is now freely available. We repeated the entire procedure described above on
that data set, and once again we observed that φM2 had the least overall bias.
Fig. 9 shows the s score for all measures across all thresholds for this dataset.
We find that, while φM2 performs better than all the other correlation measures
irrespective of thresholds, its bias is similar to that of RR for threshold fractions
0.05 and 0.1. Nevertheless, the superior performance with other thresholds gives
it the preference over RR.
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4 Methods
Our approach to the new measure starts with consideration of the relative proba-
bilities to develop one disease following another. Let η1(t) and η2(t)) be boolean
random variables corresponding to the two diseases (note the slight change in
notation from earlier) which take values 1(0) when the disease is present (ab-
sent) at time t. We want to obtain a set of relations between the probabilities
of occurrence and co-occurrence of the two diseases in the population at the
end of time τ assuming that neither disease was present at start. To that end,
we assume that the probability to be diagnosed with the disease is given by a
Poisson process. However, we assign different, a priori unknown, rates to the
Poisson process of a given disease depending on whether or not the other dis-
ease has already been diagnosed. For example, a given realization would be the
following: starting from being disease free, disease 1 is contracted at time ta
following which the Poisson rate for contracting disease 2 is different.
More specifically, if tE1(tE2) represent the time point when disease 1(2) was
diagnosed,
P (t < tE1 < t+ δt|η2(t) = 0) = λ1P δt (8)
P (t < tE1 < t+ δt|η2(t) = 1) = λ1Sδt (9)
In the first case, the primary rate λ1P determines development of disease 1 in
the absence of disease 2, but if disease 2 has been contracted before, then there
is the secondary rate λ1S . Likewise, the rate determining development of disease
2 before (after) diagnosis of disease 1 is given by λ2P (λ1S).
The conditional probabilities at finite time t:
P (η1(t) = 1|η2(t) = 0) =
P (η1(t) = 1, η2(t) = 0)
P (η2(t) = 0)
=∫ t
0
P (η1(t
′) = 0, η2(t′) = 0)P (t′ < tE1 < t′ + δt′)P (η2(t′′) = 0|t′ < t′′ < t)dt′
P (η2(t) = 0)
=∫ t
0
e−λ1P t
′
e−λ2P t
′
λ1P δt
′e−λ2S(t−t
′)
P (η2(t) = 0)
=
e−λ2St − e−(λ1P+λ2P )t
P (η2(t) = 0)(λ1P + λ2P − λ2S)
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At the end time point τ :
P (η1(τ) = 1) = P (η1(τ) = 1|η2(τ) = 0)P (η2(τ) = 0) + P (η1(τ) = 1, η2(τ) = 1)
=
e−λ2St − e−(λ1P+λ2P )t
(λ1P + λ2P − λ2S) + n12/N
= n1/N (10)
where we identify the conditional probabilities at the end point with empirical
values from the data : P (η1(τ) = 1, η2(τ) = 1) = n12/N and P (η1(τ) = 1) =
n1/N
Likewise, for disease 2:
P (η2(τ) = 1) = P (η2(τ) = 1|η1(τ) = 0)P (η1(τ) = 0) + P (η2(τ) = 1, η1(τ) = 1)
=
e−λ1St − e−(λ1P+λ2P )t
(λ1P + λ2P − λ1S) + n12/N
= n2/N (11)
We can write the probability of co-occurrence P (η1(τ) = 1, η2(τ) = 1) as a sum
of two probabilities for two mutually exclusive sets of events, one where disease
1 precedes disease 2, and second where this order is reversed.
P (η1(τ) = 1, η2(τ) = 1) =∫ τ
0
P (η1(τ) = 1|η1(tE2) = 0)P (η1(tE2) = 0, t(E2) = tE2)dtE2+∫ τ
0
P (η2(τ) = 1|t(E1) = tE1, η2(tE1) = 0)P (η2(tE1) = 0, t(E1) = tE1)dtE1
(12)
where the first(second) factors accounts for cases where diagnosis of disease 1
was made after (before) disease 2. The factors in the integrand above are :
P (η1(τ) = 1|t(E2) = tE2 , η1(tE2) = 0) = 1− e−λ1S(τ−tE2 )
P (η2(τ) = 1|t(E1) = tE1 , η1(tE1) = 0) = 1− e−λ2S(τ−tE1 )
and similarly:
P (η1(tE2) = 0, t(E2) = tE2)dtE2 = e
−λ1P tE2 e−λ2P tE2λ2P dtE2
P (η1(tE1) = 0, t(E1) = tE1)dtE1 = e
−λ2P tE1 e−λ1P tE1λ1P dtE1
Plugging this in Eq. (12), the first integral becomes:∫ τ
0
P (η1(τ) = 1|t(E2) = tE2 , η1(tE2) = 0)P (η1(tE2) = 0, t(E2) = tE2)dtE2
=
∫ τ
0
(1− e−λ1S(τ−tE2 ))e−λ1P tE2 e−λ2P tE2λ2P dtE2
=
λ2P
λ1P + λ2P
(1− e−(λ1P+λ2P )τ )− e−λ2Sτ λ2P
λ2P + λ1P − λ1S (1− e
−(λ1P+λ2P−λ2S)τ )
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If we make the approximation λiατ << 1 (W1) for i = 1, 2 and α = P, S,
then the above reduces to λ1Sλ2P τ
2/2. Correspondingly we for the the second
integral in Eq. (12) the approximation λ1Pλ2Sτ
2/2. leading to:
n12
N
=
(λ1Pλ2S + λ1Sλ2P )τ
2
2
(13)
Under the same assumption W1, we have:
e−λ2Sτ − e−(λ1P+λ2P )τ
(λ1P + λ2P − λ2S) ∼ τ − (λ1P + λ2P − λ2S)τ
2
e−λ1Sτ − e−(λ1P+λ2P )τ
(λ1P + λ2P − λ1S) ∼ τ − (λ1P + λ2P − λ1S)τ
2
Plugging the above in Eq. (10,11), we obtain :
n1/N = (λ1P τ)− λ1P λ1P + λ2P
2
τ2 − λ2Pλ1Sτ2 (14a)
n2/N = (λ2P τ)− λ2P λ1P + λ2P
2
τ2 − λ1Pλ2Sτ2 (14b)
Eqs. (13, 14) are a set of three equations but with four unknowns λiα, i =
1, 2 α = P, S, which we cannot solve without an additional simplifying as-
sumption. This is of course what we would expect, because that extra degree of
freedom corresponds to our ignorance of the underlying causal relations between
the two diseases.
For example if we use the following ansatz :
λiS = λiP q, i = 1, 2
we can solve the equations and q = n12/N(n1−n12/2)/N(n2−n12/2)/N , which would ap-
proximate to the standard definition of relative risk ( n12/minn1, n2 << 1).
Substituting λiS = λiP + qi, i = 1, 2, we can rewrite the above relations
in terms of qi which represents the deviation from the situation where the two
diseases are unrelated, i.e, qi = 0.
n1
N
= λ1P τ − (λ1P τ)
2
2
+
λ2P q1τ
2
2
n2
N
= λ2P τ − (λ2P τ)
2
2
+
λ1P q2τ
2
2
n12
N
= λ1Pλ2P τ
2 +
λ1P q2 + λ2P q1
2
τ2 (15)
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Further simplifying using A1 we have :
λ1P τ =
n1
N
− q1τ λ2P τ
2
(16a)
λ2P τ =
n2
N
− q2τ λ1P τ
2
(16b)
and plugging into Eq. (15)
n12/N =
(n1/N − q1τn2
N
)(n2/N − q2τn1
2
) +
(n1/N − q1n2τ/N)q2τ
2
+
(n2/N − q2n1τ/N)q1τ
2
) =
n1n2
N2
(1 + q1q2τ
2) +
n1q2τ
2N
(1− n1/N)− n2q1τ
2N
(1− n2
N
)− q1q2τ2n1 + n2
N
∼
n1n2
N2
+
n1q2τ
2N
+
n2q1τ
2N
where we have arrived at the third expression by dropping terms of order
n1n2
N2 qiτ ,
ni
N q1q2τ
2 and higher. Rewriting the last step,
n1q2τ + n2q1τ
N
= 2(
n12
N
− n1n2
N2
) (17)
Eq. (17) relates the two unknowns q1 and q2. As we have no other constraint
apriori, there is a family of solution to this equation. We have already examined
one example above.
Thus, we need another constraint in order to determine qi’s. We posit two
hueristic factors in this regard: one, apriori we would expect qi’s to be close to
one another, and the second, maximization of their sum. If we only had the
second criterion, then the q corresponding to be the disease with lower preva-
lence would be 0, and that of the higher prevalent disease very high. Imposing
the first criterion alone assumes a symmetry between the diseases, and while
that may be reasonable in the absence of any other information, we instead con-
sider a trade-off between them. We propose the minimization of the ”energy”
function:
E = α(q′1 − q′2)2 − β(q′1 + q′2)2 (18)
where q′i = qiτ , α, β > 0; the first term favors the q
′
i’s being close together and
the second maximizing the sum.
We look for solutions of Eqs. (17) that maximizes Eq. (18). This is done
by using the Lagrange multiplier technique for finding the extrema given a
constraint. L(q′1, q
′
2) = E + ρ(q
′
1n2/N + q
′
2n1/N − (n12/N − n1n2/N2))
∂L
∂q′1
= 2α(q′1 − q′2)− 2β(q′1 + q′2) + ρn2/N
∂L
∂q′2
= 2α(q′2 − q′1)− 2β(q′1 + q′2) + ρn1/N
14
We can now solve the above constraint equations together with Eq. 17 simul-
taneously for the three unknows q′1, q
′
2 and ρ. We give the final expressions for
q′i,i=1,2:
q′1 = 4
(
n1 + n2
Nβ
+
n1 − n2
Nα
) n12
N − n1n2N2(
n1+n2
N
)2 1
β −
(
n1−n2
N
)2 1
α
q′2 = 4
(
n1 + n2
Nβ
− n1 − n2
Nα
) n12
N − n1n2N2(
n1+n2
N
)2 1
β −
(
n1−n2
N
)2 1
α
And the sum gives us the desired measure in terms of prevalence and co-
occurrence
q′tot = q
′
1 + q
′
2 = 8
(
n1 + n2
Nβ
) n12
N − n1n2N2(
n1+n2
N
)2 1
β −
(
n1−n2
N
)2 1
α
.
This represents a family of measures parametrized by α, β > 0. Defining γ =
β/α and skipping the constant multiplicative factor of 8:
φγ =
(
n1 + n2
N
) n12
N − n1n2N2(
n1+n2
N
)2 − (n1−n2N )2 γ . (19)
For the symmetric case n1 = n2 = n, we have:
q′tot = 0.5
n12
N − n
2
N2
n
N
which, except for the factor of 0.5, is very close to what we would get with
the original φ and modified φM correlation, Eq. (4), and exact in the limit
of vanishing n/N . Although this result is independent of constants α, β, to
get reasonable answers for arbitrary ratios n2/n1, we require α/β ∼ 1 (see
Supplement).
5 Discussion
Our proposed framework to characterize the measure properties across potential
bias variables has three key features: (a) bias is characterized in terms of its
impact on selection based on effect-size (b) procedure for determining bias is
independent of the specific measure and hence comparison between measures
is carried out on a neutral platform (c) three indices are devised to capture
different aspects of the bias.
The importance of understanding the properties of measures cannot be over-
stated. Even for randomized controlled trials, conclusions depend on the mea-
sure used to characterize the effect of interventions [26]. Although not widely
recognized, it is known that most standard measures of association have sig-
nificant limitations and can give rise to misleading results unless they are in-
terpreted carefully [27]. Despite use of similar measures, the results obtained
15
from studies using different design of experiments cannot be directly compared
or combined [28]. While all these issues are certainly very relevant, we should
clarify that the measure bias that is highlighted in our work here has different
origins, and to the best of our knowledge, there has been no earlier studies that
have addressed them.
The requirement that the measure distribution be independent of prevalence
ratio could be questioned in certain limits. In the extreme case, one can argue
that, for a pair of diseases with very different prevalence nA >> nB , an unbiased
measure should never assign maximal association even when the co-occurrence
is the highest possible, nAB = nB . The basis for this is the observation that
perfect association implies the pair co-occur in every case (aside from errors
from misclassification or finiteness of study time scale), and hence divergent
prevalence would not arise in the first place. A reasonable counter-argument
would point to the potential scenario of B being an invariable cause of A. What-
ever the consensus may be on this issue, most realistic situations contain very
few or no such cases, and in large cohorts the relations in the generic pair fol-
low nAB << min{nA, nB} where one would expect measure distribution to be
independent of prevalence ratio.
16
A A¯
B p q nB = p+ q
B¯ r s nB¯ = r + s
nA = p+ r nA¯ = q + s N = p+ q + r + s
Table 1: Contingency table for a pair of diseases in a cohort
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Figure 1: (a)Variation of RR as function of the expected co-occurrence shown
as a box plot for all the pairs that fill within the particular window of expected
co-occurrence. (b) The same analysis repeated for φ correlation.
Figure 2: (a) Fraction of pairs above a certain fixed threshold (corresponding to
1% selection among all pairs) within each partition of the bias variable (expected
co-occurrences) for RR and φ correlation measures. (b) Characterizing the
variation of fractions across the different partitions using three indices.
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Figure 3: Fraction of pairs above a certain fixed threshold (corresponding to 1%
selection among all pairs) within each partition of the bias variable (prevalence
ratio, n<n> , where n<(n>) is the prevalence of the less (more) frequent disease)
for RR and φ correlation measures. (b) Characterizing the variation of fractions
across the different partitions using three indices.
Figure 4: (a) Variation of fractions with prevalence ratios for the original corre-
lation φ and its modification φM . We find that the φM has its own bias inflating
the significant fractions for smaller prevalence ratios, which is the opposite of
the original measure. (b) The variation of fractions characterized by the three
indices.
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Figure 5: (a)Variation of fractions with prevalence ratios across φ, φM and φM2.
(b) The same is characterized by the three indices.
20
Figure 6: The three indices (a) Interquartile Range (b) Mean Absolute Deviation
and (c)Q9Q1 of the fractions obtained for the bias with respect to the prevalence
ratio, for different overall (full data) fractions (x-axis) and for all the measures.
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Figure 7: The three indices (a) Interquartile Range (b) Mean Absolute Devia-
tion and (c)MinMax of the fractions obtained for the bias with respect to the
expected co-occurrences, for different overall (full data) fractions (x-axis) and
for all the measures.
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Figure 8: Variation of the combined bias score s for measures RR, φ, φM and
φM2 and across overall threshold fractions 0.001,0.005,0.01,0.05 and 0.01.
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Figure 9: Variation of the combined bias score s for measures RR, φ, φM and
φM2 and across overall threshold fractions 0.001,0.005,0.01,0.05 and 0.01 calcu-
lated on the U.S. Medicare data.
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Appendices
A Effect of parameter γ on measure bias
We consider how the measure properties change as we modify the value of the
parameter γ in Eq. 5 (main text). In particular, we are interested in the
dependence of measure biases on γ. However, as we we have observed earlier,
ranking of measures based on magnitude of bias defined by the three indices
are not concordant. Following our approach to compare different measures in
the main text, we use the score s (Eq. 7 in main text) to captures the net bias
from the three indices and for both bias variables. Fig. 10 shows the variation
of s with γ for the different thresholds. We find that the minimum is attained
at γ = 1 in almost every case. In fact, the only deviation from γ = 1 occurs
at threshold fraction of 0.001, and even here the minima is attained nearby at
1.025.
Besides the explicit comparisons using the score s, there is an intuitive reason
for selecting γ = 1. In the derivation of the measure, we find that γ enters in
the “energy” equation whose minimization provides the additional constraint
necessary to solve for the measure. Setting γ = 1, equivalently α = β in Eq.
19 makes the two terms symmetric. In addition, the final expression obtained
has a greater intuitive appeal, being symmetric in n1, n2 and being free of any
unwieldy constants. Moreover, when n1 = n2 = n, this is equivalent to the
original φ and φM except for a term of order O(n/N) which in most realistic
cases is negligible. Also, for unequal prevalence, n2 < n1 the maximum value of
the measure is
φM2(n12 = n2) =
1
4
(
1 +
n2
n1
)(
1− n1
N
)
.
Ignoring the last factor, its range is between 0.25 (in the limit n2 → 0) and
0.5 (equal prevalence). This places the measure in-between φ (maximum dimin-
ishes to 0 when n2 → 0) and φM (maximum is uniformly unity for all pairs of
prevalence).
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Figure 10: Variation of the combined bias score s of the three indices with the
parameter γ (in the new measure family) across different thresholds.
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B Poisson Distribution of disease co-occurrence
Here we show that distribution of co-occurrences for a given pair of diseases
with specified incidence rates under the null hypothesis that the two diseases
are completely independent, is in fact, Poisson.
Concretely, if N is total population of the cohort, and ni represents the number
of people with disease i (i = 1, 2, · · ·M), and if all diseases are uncorrelated with
each other and occur randomly in the population, the total number of ways in
which we can have an overlap of nij individuals carrying both diseases i and j
is given by:
C(ni, nj , nij , N) =
(
N
ni
)(
ni
nij
)(
N − ni
nj − nij
)
=
N !
(ni − nij)!(nj − nij)!nij !(N + nij − ni − nj)! (20)
where the first factor corresponds to choosing ni elements (first set) from N , the
second, the intersecting nij elements among the ni, and the third, the nj − nij
elements (second set - overlapping elements) from the remainingN−ni elements.
Taking the log on both sides and using the Sterling approximation logN ! =
N logN −N ,
logC(ni, nj , nij , N) = N logN − ni(1− nij
ni
) log ni(1− nij
ni
)− nj(1− nij
nj
) log nj(1− nij
nj
)
− nij log nij − (N − ni − nj)(1 + nij
N − ni − nj ) log (N − ni − nj)(1 +
nij
N − ni − nj )
(21)
Simplifying and retaining only terms that are first order in nij or higher:
logC(ni, nj , nij , N) = logC0 + nij(1 + log
ninj
N − ni − nj − log nij) (22)
Exponentiating, and using the Sterling approximation in reverse, we get:
C =
C0
nij !
(
ninj
N − ni − nj
)nij
(23)
which is nothing but the Poisson distribution with (average E(nij) = λ =
ninj
N−ni−nj and the constant C0 would be normalized to e
−λ.
This is of course what we would expect from naive considerations of probability
theory. Thus one can calculate p-values from that of the Poisson distribution
27
the p-value corresponding to an observation nij , then comes from the cumulative
distributive function of Poisson :
F (nij) =
∑
k≥nij
PPoiss(nij , λ) (24)
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